AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Autolus Therapeutics plc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$1.59−0.01 (-0.63%)

Close on Oct 19, 2026

Market cap: $423.19M
P/E (TTM): –
Dividend yield: –

Autolus Therapeutics plc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2018 2018-09-30	FY 2017 2017-09-30	FY 2016 2016-09-30
Revenue	75	10	1.70	–	–	–	1.41	1.69	1.21
Cost of Revenue	96	11	0	–	–	–	–	–	–
Gross Profit	-21	-1.27	1.70	–	–	–	–	–	–
Research & Development	118	138	130	117	111	135	36	16	10
Selling, General & Admin	132	102	47	–	–	–	–	–	–
General & Administrative	–	–	47	32	32	35	23	9.10	5.15
Operating Expenses	–	–	–	–	–	–	58	23	14
Operating Income	-271	-241	-180	-143	-141	-168	-58	-23	–
Interest Expense	37	9.29	45	8.91	1.11	0	–	–	–
Interest & Investment Income	19	32	14	1.71	0.26	0.54	1.53	0.08	0.08
Other Non-Operating Income	-15	22	-29	-5.16	-0.99	1.89	5.50	0.04	0.05
Merger & Restructuring Charges	2.40	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	0.40	0	0	0	–	–	–
Gain (Loss) on Sale of Assets	-0.01	-0.22	-3.79	-0.52	-0.68	0	-0.01	0	0
Pretax Income	-286	-219	-208	-149	-142	-166	-52	-23	-14
Income Tax Expense	1.97	1.53	-0.02	0.27	0.06	-24	-7.28	-3.65	-1.78
Net Income	-288	-221	-208	-149	-142	-142	-45	-20	-13
Net Income to Common	-288	-221	-208	-149	-142	-142	–	–	–
EPS (Basic)(per share)	-1.08	-0.86	-1.20	-1.57	-1.97	-2.76	-1.42	-1.43	-1.26
EPS (Diluted)(per share)	-1.08	-0.86	-1.20	-1.57	-1.97	-2.76	-1.42	-1.43	-1.26
Shares Outstanding (Basic, Weighted)(shares)	266	255	174	95	72	52	32	14	9.93
Shares Outstanding (Diluted, Weighted)(shares)	266	255	174	95	72	52	32	14	9.93
EBITDA	-262	-234	-173	-136	-133	-162	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 15.7%
Operating margin: -210.8%
Net margin: -238.7%
Return on equity, FY2025: -95.0%

Financial strength

Current ratio: 4.89
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 249.2%

Valuation

P/E ratio: –
Price to sales: 3.61
Price to book: 5.65
Dividend yield: –